291 related articles for article (PubMed ID: 24013976)
1. Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting.
Chiha M; Myers LE; Ball CA; Sinacore JM; Camacho PM
Endocr Pract; 2013; 19(6):989-94. PubMed ID: 24013976
[TBL] [Abstract][Full Text] [Related]
2. OSTEOPOROTIC FRACTURES DURING BISPHOSPHONATE DRUG HOLIDAY.
Bindon B; Adams W; Balasubramanian N; Sandhu J; Camacho P
Endocr Pract; 2018 Feb; 24(2):163-169. PubMed ID: 29144808
[TBL] [Abstract][Full Text] [Related]
3. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
4. Effect of bisphosphonates on bone mineral density and fracture prevention in gastric cancer patients after gastrectomy.
Lim JS; Jin SH; Kim SB; Lee JI
J Clin Gastroenterol; 2012 Sep; 46(8):669-74. PubMed ID: 22504799
[TBL] [Abstract][Full Text] [Related]
5. Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting.
Roberts J; Castro C; Moore AE; Fogelman I; Hampson G
Clin Endocrinol (Oxf); 2016 Apr; 84(4):509-15. PubMed ID: 26715263
[TBL] [Abstract][Full Text] [Related]
6. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
Mok J; Brown C; Moore AEB; Min SS; Hampson G
Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of bone mineral density testing and osteoporosis management following low- and high-energy fractures.
Angthong C; Rodjanawijitkul S; Samart S; Angthong W
Acta Orthop Traumatol Turc; 2013; 47(5):318-22. PubMed ID: 24164940
[TBL] [Abstract][Full Text] [Related]
8. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
[TBL] [Abstract][Full Text] [Related]
9. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
Geller JL; Hu B; Reed S; Mirocha J; Adams JS
Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
[TBL] [Abstract][Full Text] [Related]
11. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW
Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
[TBL] [Abstract][Full Text] [Related]
12. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use.
Weil YA; Rivkin G; Safran O; Liebergall M; Foldes AJ
J Trauma; 2011 Jul; 71(1):186-90. PubMed ID: 21610533
[TBL] [Abstract][Full Text] [Related]
13. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
McClung M
Clin Obstet Gynecol; 2013 Dec; 56(4):743-8. PubMed ID: 24177063
[TBL] [Abstract][Full Text] [Related]
14. Atypical femur fracture during bisphosphonate drug holiday: a case series.
Lovy AJ; Koehler SM; Keswani A; Joseph D; Hasija R; Ghillani R
Osteoporos Int; 2015 Jun; 26(6):1755-8. PubMed ID: 25832177
[TBL] [Abstract][Full Text] [Related]
15. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
Sebba AI
Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
[TBL] [Abstract][Full Text] [Related]
16. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis.
Pinzone MR; Moreno S; Cacopardo B; Nunnari G
AIDS Rev; 2014; 16(4):213-22. PubMed ID: 25300622
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
Hasegawa E; Ito S; Takai C; Kobayashi D; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
Intern Med; 2018 Aug; 57(15):2169-2178. PubMed ID: 29607978
[TBL] [Abstract][Full Text] [Related]
19. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
Deane A; Constancio L; Fogelman I; Hampson G
BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
[TBL] [Abstract][Full Text] [Related]
20. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
Nasomyont N; Hornung LN; Gordon CM; Wasserman H
Bone; 2019 Apr; 121():60-67. PubMed ID: 30616029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
